Pasar al contenido principal

DISECCIONANDO EL PAPEL DE NPC2 Y CD109, DOS NUEVOS EFECTORES DE METASTASIS, EN CANCER COLORRECTAL

PID2021-122227OB-I00

•
Nombre agencia financiadora Agencia Estatal de Investigación
Acrónimo agencia financiadora AEI
Programa Programa Estatal para Impulsar la Investigación Científico-Técnica y su Transferencia
Subprograma Subprograma Estatal de Generación de Conocimiento
Convocatoria Proyectos de I+D+i (Generación de Conocimiento y Retos Investigación)
Año convocatoria 2021
Plan Estatal 2021-2023 Plan Estatal de Investigación Científica y Técnica y de Innovación
Centro beneficiario AGENCIA ESTATAL CONSEJO SUPERIOR DE INVESTIGACIONES CIENTIFICAS (CSIC)

Resultados relacionados

Resultados totales (Incluyendo duplicados): 5
Encontrada(s) 1 página(s)

DIGITAL.CSIC. Repositorio Institucional del CSIC
Publicación Artículo científico (JournalArticle)

Integrated meta-analysis of colorectal cancer public proteomic datasets for biomarker discovery and validation

  • Robles, Javier
  • Prakash, Ananth
  • Vizcaíno, Juan Antonio
  • Casal, J. Ignacio
24 p.-8 fig.-2 tab., The cancer biomarker field has been an object of thorough investigation in the last decades. Despite this, colorectal cancer (CRC) heterogeneity makes it challenging to identify and validate effective prognostic biomarkers for patient classification according to outcome and treatment response. Although a massive amount of proteomics data has been deposited in public data repositories, this rich source of information is vastly underused. Here, we attempted to reuse public proteomics datasets with two main objectives: i) to generate hypotheses (detection of biomarkers) for their posterior/downstream validation, and (ii) to validate, using an orthogonal approach, a previously described biomarker panel. Twelve CRC public proteomics datasets (mostly from the PRIDE database) were re-analysed and integrated to create a landscape of protein expression. Samples from both solid and liquid biopsies were included in the reanalysis. Integrating this data with survival annotation data, we have validated in silico a six-gene signature for CRC classification at the protein level, and identified five new blood-detectable biomarkers (CD14, PPIA, MRC2, PRDX1, and TXNDC5) associated with CRC prognosis. The prognostic value of these blood-derived proteins was confirmed using additional public datasets, supporting their potential clinical value. As a conclusion, this proof-of-the-concept study demonstrates the value of re-using public proteomics datasets as the basis to create a useful resource for biomarker discovery and validation. The protein expression data has been made available in the public resource Expression Atlas., This project was supported by grants RTI2018-095055-B-I00, PID2021-122227OB-I00 and PDC2022-133056-I00 from the Ministerio de Ciencia e Innovación (MCIN/AEI/10.13039/501100011033) using Next Generation EU/PRTR funds to JIC, and BBSRC grant number BB/T019670/1 and EMBL core funding to JAV. JR was supported by IND2019/BMD-17153 fellowship of the Comunidad de Madrid., Peer reviewed
DIGITAL.CSIC. Repositorio Institucional del CSIC
Publicación Artículo científico (JournalArticle)

A complex of cadherin 17 with desmocollin 1 and p120-catenin regulates colorectal cancer migration and invasion according to the cell phenotype

  • Bartolomé, Rubén Álvaro
  • Pintado-Berninches, Laura
  • Martin-Regalado, Ángela
  • Robles, Javier
  • Calvo-López, Tania
  • Ortega-Zapero, Marina
  • Llorente-Sáez, Celia
  • Boukich, Issam
  • Fernandez-Aceñero, M. Jesús
  • Casal, J. Ignacio
17 p.-7 fig., Background: Cadherin-17 (CDH17), a marker of differentiation in intestinal cells, binds and activates α2β1 integrin to promote cell adhesion and proliferation in colorectal cancer (CRC) metastasis. Furthermore, CDH17 associates with p120- and β-catenin in a manner yet to be fully elucidated. In this report, we explored the molecular mediators involved in this association, their contribution to CRC dissemination and potential therapeutic implications., Methods: Proteomic and confocal analyses were employed to identify and validate CDH17 interactors. Functional characterization involved the study of proliferation, migration, and invasion in cell lines representative of various phenotypes. Immunohistochemistry was conducted on CRC tissue microarrays (TMA). In vivo animal experiments were carried out for metastatic studies., Results: We found that desmocollin-1 (DSC1), a desmosomal cadherin, interacts with CDH17 via its extracellular domain. DSC1 depletion led to increased or decreased invasion in CRC cells displaying epithelial or mesenchymal phenotype, respectively, in a process mediated by the association with p120-catenin. Down-regulation of DSC1 resulted in an increased expression of p120-catenin isoform 1 in epithelial cells or a shift in cellular location in mesenchymal cells. Opposite results were observed after forced expression of CDH17. DSC1 is highly expressed in budding cells at the leading edge of the tumor and associates with poor prognosis in the stem-like, mesenchymal CRC subtypes, while correlates with a more favorable prognosis in the less-aggressive subtypes. In vivo experiments demonstrated that DSC1 silencing reduced tumor growth, liver homing, and metastasis in CRC mesenchymal cells. Furthermore, a synthetic peptide derived from CDH17, containing the NLV motif, effectively inhibited invasion and liver homing in vivo, opening up new possibilities for the development of novel therapies focused on desmosomal cadherins., Conclusions: These findings shed light on the multifaceted roles of CDH17, DSC1, and p120-catenin in CRC metastasis, offering insights into potential therapeutic interventions for targeting desmosomal cadherins in poorly-differentiated carcinomas., Open Access funding provided thanks to the CRUE-CSIC agreement with Springer Nature. Laura Pintado-Berninches was supported by a Margarita Salas contract (CA1/RSUE/2021–00208) from the Ministry of Universities (Spain). Angela Martín-Regalado was supported by a FPU fellowship (FPU18/05766-MEFP). Javier Robles and Issam Boukich were supported by IND2019/BMD-17153 and IND2022/BMD-23554 fellowship grants of the Comunidad de Madrid. This project was supported by grants RTI2018-095055-B-I00 and PID2021-122227OB-I00 from the MCIN/AEI/https://doi.org/10.13039/501100011033 and by the grant PMPTA22/00108 from Instituto de Salud Carlos III using Next Generation EU/PRTR funds., Peer reviewed
DIGITAL.CSIC. Repositorio Institucional del CSIC
Publicación Artículo científico (JournalArticle)

Loss of cadherin 17 downregulates LGR5 expression, stem cell properties and drug resistance in metastatic colorectal cancer cells

  • Bartolomé, Rubén Álvaro
  • Pintado-Berninches, Laura
  • Robles, Javier
  • Calvo-López, Tania
  • Boukich, Issam
  • Otero-Núñez, Pablo
  • González-Sancho, José Manuel
  • Casal, J. Ignacio
13 p.-8 fig., Cadherin 17 (CDH17) plays a crucial role in the metastatic progression of colorectal cancer (CRC) through its interaction with α2β1 integrin and desmocollin 1. To further elucidate the molecular mechanisms involving CDH17 functions in CRC, we examined global expression alterations following CDH17 silencing in various metastatic cell lines. Loss of CDH17 resulted in a marked down-regulation of the intestinal cancer stem cell (CSC) marker LGR5, leading to the inhibition of Wnt/β-catenin signaling, suppression of pluripotency genes such as MYC, and a subsequent reduction in stemness properties. Treatment with CDH17/integrin blocking antibodies produced similar effects, decreasing both, LGR5 expression and Wnt signaling. CDH17 silencing also down-regulated various transporters associated with drug-resistance, including the glutamine-transporter SLC38A5. Consequently, the loss of CDH17 increased sensitivity to 5-FU, irinotecan, oxidative stress and anoikis in CRC cells. Notably, SLC38A5 silencing was necessary for CDH17-driven effects on drug resistance and survival. Pharmacological inhibition of SLC38A5 with amiloride, significantly increased cell sensitivity to 5-FU and irinotecan, and improved mouse survival in metastasis models. In conclusion, CDH17 plays a crucial role in maintaining colorectal cancer cell stemness and chemoresistance via LGR5/Wnt/MYC signaling and SLC38A5 expression. These findings underscore the therapeutic potential of CDH17 targeting in metastatic CRC, and support the use of amiloride for inhibiting liver metastasis., Laura Pintado-Berninches was supported by a Margarita Salas contract (CA1/RSUE/2021-00208) from the Ministry of Universities (Spain). Javier Robles and Issam Boukich were supported by IND2019/BMD-17153 and IND2022/BMD-23554 fellowship grants of the Comunidad de Madrid, respectively. This project was supported by the grants PID2021-122227OB-I00 of the Ministerio de Ciencia e Innovación (Spain) and PMPTA22/00108 from Instituto de Salud Carlos III using Next Generation EU/PRTR funds from the MCIN/AEI/10.13039/501100011033, and grant S2022/BMD-7212 funded by the Comunidad de Madrid, Peer reviewed
DIGITAL.CSIC. Repositorio Institucional del CSIC
Publicación Artículo científico (JournalArticle)

The emerging role of human transmembrane RGD-based counter-receptors of integrins in health and disease

  • Cabañas, Carlos
  • Rossi, Elisa
  • Bartolomé, Rubén Álvaro
  • Doberstein, Kai
  • Altevogt, Peter
  • Casal, J. Ignacio
  • Bernabéu, Carmelo
Most of the canonical Arg-Gly-Asp (RGD)-containing integrin ligands are extracellular matrix proteins, such as fibronectin, vitronectin and fibrinogen, which regulate cell-ECM adhesion processes. However, during the last years, several reports have demonstrated the existence of non-canonical RGD-containing integrin ligands that are cell surface transmembrane proteins. At variance with the canonical extracellular matrix integrin ligands, the RGD-containing cell surface integrin ligands are involved in cell-cell adhesion processes and function as "integrin counter-receptors". We propose in this review grouping these transmembrane proteins, which include endoglin, cadherin-5, cadherin-6, cadherin-17, ADAM15, and L1CAM, under the newly coined acronym RGD-ICRs (RGD-containing Integrin Counter-Receptors). We present and discuss the structure of RGD-ICRs, their RGD-based interactions with integrins, the specific signaling pathways triggered in different cell types, as well as their pathophysiological involvement. It can be postulated that RGD-ICRs constitute an emerging group of non-canonical RGD-based integrin counter-receptors. In spite of being encoded by different and independent genes and involved in different pathophysiological processes, all of them appear to have undergone a strong evolutionary convergence in order to acquire the same functional capacity to bind integrins via the RGD motif. Importantly, these RGD-ICRs are also emerging as novel biomarkers and therapeutic targets, with promising clinical potential in a wide array of pathologies., C.C. was supported by grant no. PID2021-123199OB-I00 of the Ministerio de Ciencia e Innovaci\u00F3n (Spain) (MCIN/AEI/https://doi.org/10.13039/501100011033) and by the European Union. The CBM-SO is a \u201CSevero Ochoa Center of Excellence\u201D (grant no. CEX2021-001154-S) funded by MICIN/AEI/https://doi.org/10.13039/501100011033 and receives an institutional grant from the Fundaci\u00F3n Ram\u00F3n Areces. J.I.C. was supported by grant nos. PID2021-122227OB-I00 of the Ministerio de Ciencia e Innovaci\u00F3n (Spain) and PMPTA22/00108 from the Instituto de Salud Carlos III using Next Generation EU/PRTR funds from the MCIN/AEI/https://doi.org/10.13039/501100011033. C.B. was supported by the Consejo Superior de Investigaciones Cient\u00EDficas (CSIC, Spain) (grant no. 201920E022)., Peer reviewed
DIGITAL.CSIC. Repositorio Institucional del CSIC
Publicación Artículo científico (JournalArticle)

CD109 Drives Stemness and Chemoresistance in Colorectal Cancer via LRRC8A/AKAP12/PKCα-Mediated STAT3 Activation and WNT Signaling

  • Bartolomé, Rubén Álvaro
  • Calvo-López, Tania
  • Otero-Núñez, Pablo
  • Estaras, María
  • Fernández-Barral, Asunción
  • Barbáchano, Antonio
  • Boukich, Issam
  • Cuerda-López, María
  • Fernández-Aceñero, Mª Jesús
  • Rodríguez-Urquirizar, Gorane
  • Mariscal-Casero, Ana
  • Padilla-Blanco, Miguel
  • Montoya, María
  • O'Loghlen, Ana
  • Fernández-Fernández, José M
  • Gonzalez-Sancho, Jose Manuel
  • Casal, J Ignacio
Colorectal cancer (CRC) is the third most prevalent type of cancer worldwide, with a poor survival rate at the metastatic stage. Here, we identify CD109-a negative regulator of TGFβ signaling-as a key driver of stemness and drug resistance through modulation of Wnt signaling in advanced CRC. CD109 expression strongly correlates with TGFβ levels in patient tumors and is enriched in the aggressive CRIS-B subtype, where it associates with poor clinical outcome. CD109 silencing reduced STAT3 phosphorylation and cell proliferation, without affecting migration or invasion. Moreover, global expression analysis revealed downregulation of various hallmarks of cancer stemness (i.e. LGR5 expression), together with increased TGFβ signaling and cellular senescence. Mechanistically, CD109 interacts with LRRC8A, a subunit of the volume-regulated anion channel (VRAC), which associates with AKAP12 to activate PKCα and promote STAT3 phosphorylation. This CD109/LRRC8A/AKAP12/PKCα axis sustains Wnt signaling, stemness, and drug resistance. Consistently, co-expression of CD109/LRRC8A/AKAP12 correlates with poor prognosis in CRC patients. Genetic or pharmacological disruption of this CD109/LRRC8A/AKAP12/PKCα axis impaired STAT3 signaling, reduced LGR5 expression and Wnt signaling, and sensitized cells to chemotherapy. In vivo, CD109 or LRRC8A knockdown significantly impaired liver homing and metastatic colonization in mouse models, showing stronger effects in Swiss nude mice than in highly immunodeficient NSG mice. Collectively, these findings support CD109 as a central regulator for STAT3-driven stemness and chemoresistance in advanced CRC, via the LRRC8A/AKAP12/PKCα axis, and highlight its potential value as a therapeutic target in metastatic disease., PON was supported by a Juan de la Cierva contract from the Ministry of Science, Innovation and Universities (MICIU) (Spain). IB and MC were supported by IND2022/BMD-23554 and IND2024/ BMD-34329 fellowship grants of the Comunidad de Madrid. AMC was funded by a PhD fellowship Ramon Areces (BTVP25S22277). JMFF´s lab was funded by the Spanish Ministry of Science and Innovation (MCIN)/State Research Agency (AEI, Agencia Estatal de Investigación)/10.13039/ 501100011033/, and FEDER Funds (Fondo Europeo de Desarrollo Regional) (grant PID2022-136546OB-I00 to J.M.F-F); “Unidad de Excelencia María de Maeztu” CEX2024-001431-M, funded by MICIU/AEI/ 10.13039/501100011033. AO’s lab was supported by projects CNS2022-135134 and PID2021-125656OB-I00 financed by MICIU/AEI/10.13039/501100011033, 10.13039/501100011033 and by project SenesceX S2022/BMD-7393 financed by the Comunidad de Madrid. JIC´s lab was supported by grants PID2021- 122227OB-I00 and PID2024-156301OB-I00 (MICIU) with funds MCIN/AEI/10.13039/501100011033 and “Next-Generation EU”/PRTR, and grant S2022/BMD-7212 funded by the Comunidad de Madrid (Spain). Ethics approval and consent to participate The collection of patient-derived samples for, Peer reviewed, Modelo experimental animal, Modelo experimental alternativo-NAM, Mamíferos - Roedores, in silico, in vitro - Tipos celulares - líneas inmortalizadas humanas, in vitro - Sistemas de cultivo - Cultivos 3D - organoides